TrialBritish journal of cancer2026

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

Chia-Jui Yen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.